Opinion|Videos|September 19, 2024
Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices
Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- If a patient continues to cycle tumor necrosis factor inhibitors (TNFis) and does not achieve remission, how do complications, such as irreversible joint erosion, potentially affect patient quality of life?
- With the wide range of treatment options, why do you think providers are continuing to choose a second or even a third TNFi after the first fails?
- Are there access barriers to switching mechanism of action (MOA)? What are other barriers to care exist when switching to another MOA vs cycling a TNF?
- What treatment considerations do you give to a patient who initially responds well to a TNFi but the response wanes over time?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
Advertisement
Advertisement